Core-shell nanotherapeutics with leukocyte membrane camouflage for biomedical applications

References

• Yang G, Liu Y, Wang H, et al. Bioinspired core-shell nanoparticles for hydrophobic drug delivery. Angew Chem Int Ed. 2019;58(40):14357–14364.
   PubMed Web of Science ®Google Scholar
• Panday R, Poudel AJ, Li X, et al. Amphiphilic core-shell nanoparticles: synthesis, biophysical properties, and applications. Colloid Surface B. 2018;172:68–81.
   PubMed Web of Science ®Google Scholar
• Zingg R, Fischer M. The consolidation of nanomedicine. Wires Nanomed Nanobi. 2019;11(6):e1569.
   Web of Science ®Google Scholar
• Awasthi R, Roseblade A, Hansbro PM, et al. Nanoparticles in cancer treatment: opportunities and obstacles. Curr Drug Targets. 2018;19(14):1696–1709.
   PubMed Web of Science ®Google Scholar
• Li B, Lane LA. Probing the biological obstacles of nanomedicine with gold nanoparticles. WIREs Nanomed Nanobiotechnol. 2019;11(3):e1542.
   PubMed Web of Science ®Google Scholar
• AlQahtani AD, O’Connor D, Domling A, et al. Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomed Pharmacother. 2019;113:108750.
   PubMed Web of Science ®Google Scholar
• Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mat. 2019;20(1):710–724.
   PubMed Web of Science ®Google Scholar
• Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. WIREs Nanomed Nanobiotechnol. 2015;7(5):655–677.
   PubMed Web of Science ®Google Scholar
• Ai X, Hu M, Wang Z, et al. Recent advances of membrane-cloaked nanoplatforms for biomedical applications. Bioconjugate Chem. 2018;29(4):838–851.
   PubMed Web of Science ®Google Scholar
• Narain A, Asawa S, Chhabria V, et al. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine-UK. 2017;12(21):2677–2692.
   PubMed Web of Science ®Google Scholar
• Yurkin ST, Wang Z. Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery. Nanomedicine-UK. 2017;12(16):2007–2019.
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. P Natl Acad Sci USA. 2011;108(27):10980–10985.
   PubMed Web of Science ®Google Scholar
• Pasto A, Giordano F, Evangelopoulos M, et al. Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy. Clin Transl Med. 2019;8(1):8.
   PubMed Web of Science ®Google Scholar
• Wu HH, Zhou Y, Tabata Y, et al. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release. 2019;294:102–113.
   PubMed Web of Science ®Google Scholar
• Banskota S, Yousefpour P, Chilkoti A. Cell-based biohybrid drug delivery systems: the best of the synthetic and natural worlds. Macromol Biosci. 2017;17(1):1600361.
   Web of Science ®Google Scholar
• Li R, He Y, Zhang S, et al. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm Sin B. 2018;8(1):14–22.
   PubMed Web of Science ®Google Scholar
• Filippi MD. Mechanism of diapedesis: importance of the transcellular route. Adv Immunol. 2016;129:25–53.
   PubMed Web of Science ®Google Scholar
• Croci DO, Zacarias Fluck MF, Rico MJ, et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56(11):1687–1700.
   PubMed Web of Science ®Google Scholar
• Kroll AV, Fang RH, Zhang L. Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjugate Chem. 2017;28(1):23–32.
   PubMed Web of Science ®Google Scholar
• Dawson KA, Yan Y. Drug delivery: leukocyte-like carriers. Nature Mater. 2016;15(9):935–936.
   PubMed Web of Science ®Google Scholar
• Fukuta T, Yoshimi S, Tanaka T, et al. Leukocyte-mimetic liposomes possessing leukocyte membrane proteins pass through inflamed endothelial cell layer by regulating intercellular junctions. Int J Pharmaceu. 2019;563:314–323.
   PubMed Web of Science ®Google Scholar
• Molinaro R, Corbo C, Martinez JO, et al. Biomimetic proteolipid vesicles for targeting inflamed tissues. Nature Mater. 2016;15(9):1037–1046.
   PubMed Web of Science ®Google Scholar
• Martinez JO, Molinaro R, Hartman KA, et al. Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics. 2018;8(4):1131–1145.
   PubMed Web of Science ®Google Scholar
• Arrighetti N, Corbo C, Evangelopoulos M, et al. Exosome-like nanovectors for drug delivery in cancer. Curr Med Chem. 2019;26(33):6132–6148.
   PubMed Web of Science ®Google Scholar
• Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10(4):218.
   PubMed Web of Science ®Google Scholar
• Baek SK, Makkouk AR, Krasieva T, et al. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol. 2011;104(2):439–448.
   PubMed Web of Science ®Google Scholar
• Stephan MT, Moon JJ, Um SH, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035–1041.
   PubMed Web of Science ®Google Scholar
• Huang Y, Gao X, Chen J. Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharm Sin B. 2018;8(1):4–13.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Leukocytes as carriers for targeted cancer drug delivery. Expert Opin Drug Del. 2015;12(3):375–392.
   PubMed Web of Science ®Google Scholar
• Dong X, Chu D, Wang Z. Leukocyte-mediated delivery of nanotherapeutics in inflammatory and tumor sites. Theranostics. 2017;7(3):751–763.
   PubMed Web of Science ®Google Scholar
• Fang RH, Kroll AV, Gao W, et al. Cell membrane coating nanotechnology. Adv Mater. 2018;30(23):e1706759.
   PubMed Web of Science ®Google Scholar
• Coillard A, Segura E. In vivo differentiation of human monocytes. Front Immuno. 2019;10:1907.
   PubMed Web of Science ®Google Scholar
• Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity. 2018;49(4):595–613.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Myasoedova VA, Revin VV, et al. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology. 2018;223(1):101–111.
   PubMed Web of Science ®Google Scholar
• Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78.
   PubMed Web of Science ®Google Scholar
• Yan H, Shao D, Lao YH, et al. Engineering cell membrane-based nanotherapeutics to target inflammation. Adv Sci. 2019;6(15):1900605.
   Web of Science ®Google Scholar
• Dehne N, Mora J, Namgaladze D, et al. Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr Opin Pharmacol. 2017;35:12–19.
   PubMed Web of Science ®Google Scholar
• Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nature Nanotech. 2013;8(1):61–68.
   PubMed Web of Science ®Google Scholar
• Palomba R, Parodi A, Evangelopoulos M, et al. Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability. Sci Rep. 2016;6:34422.
   PubMed Web of Science ®Google Scholar
• Evangelopoulos M, Parodi A, Martinez JO, et al. Cell source determines the immunological impact of biomimetic nanoparticles. Biomaterials. 2016;82:168–177.
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthcare Mater. 2015;4(11):1645–1652.
   Web of Science ®Google Scholar
• Krishnamurthy S, Gnanasammandhan MK, Xie C, et al. Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale. 2016;8(13):6981–6985. 7
   PubMed Web of Science ®Google Scholar
• Cao H, Dan Z, He X, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738–7748.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai K, Li C, et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett. 2018;18(3):1908–1915.
   PubMed Web of Science ®Google Scholar
• Rao L, He Z, Meng QF, et al. Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles. J Biomed Mater Res. 2017;105(2):521–530.
   Web of Science ®Google Scholar
• Doughty ACV, Hoover AR, Layton E, et al. Nanomaterial applications in photothermal therapy for cancer. Materials. 2019;12(5):779.
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8(15):9610–9618.
   PubMed Web of Science ®Google Scholar
• Meng QF, Rao L, Zan M, et al. Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy. Nanotechnology. 2018;29(13):134004.
   PubMed Web of Science ®Google Scholar
• Thamphiwatana S, Angsantikul P, Escajadillo T, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci USA. 2017;114(43):11488–11493.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wei W, Wang P, et al. Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy. ACS Nano. 2017;11(11):10724–10732.
   PubMed Web of Science ®Google Scholar
• Borrie AE, Vareki M. S. T lymphocyte-based cancer immunotherapeutics. Int Rev Cell Mol Bio. 2018;341:201–276.
   PubMed Web of Science ®Google Scholar
• Chraa D, Naim A, Olive D, et al. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol. 2019;105(2):243–255.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Teng Y, Samykutty A, et al. Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol Ther. 2015;24(1):96–105.
   PubMed Web of Science ®Google Scholar
• Han Y, Pan H, Li W, et al. T Cell membrane mimicking nanoparticles with bioorthogonal targeting and immune recognition for enhanced photothermal therapy. Adv Sci. 2019;6(15):1900251.
   Web of Science ®Google Scholar
• Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75(4):689–713.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhang G, Ran D, et al. T-Cell-mimicking nanoparticles can neutralize HIV infectivity. Adv Mater. 2018;30(45):e1802233.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li R, Chen H, et al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. IJN. 2017;12:2129–2142.
   Web of Science ®Google Scholar
• Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1146.
   PubMed Web of Science ®Google Scholar
• Triner D, Shah YM. Hypoxic Regulation of Neutrophils in Cancer. Int J Mol Sci. 2019;20(17):4189.
   Web of Science ®Google Scholar
• Chu D, Dong X, Shi X, et al. Neutrophil-based drug delivery systems. Adv Mater. 2018;30(22):e1706245.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhao R, Xu F. Neutrophil-based delivery systems for nanotherapeutics. Small. 2018;14(42):e1801674.
   PubMed Web of Science ®Google Scholar
• Tayoun T, Faugeroux V, Oulhen M, et al. CTC-derived models: a window into the seeding Capacity of Circulating Tumor Cells (CTCs). Cells. 2019;8(10):1145.
   Web of Science ®Google Scholar
• Fabisiewicz A, Grzybowska E. CTC clusters in cancer progression and metastasis. Med Oncol. 2017;34(1):12.
   PubMed Web of Science ®Google Scholar
• Spicer JD, McDonald B, Cools-Lartigue JJ, et al. Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012;72(16):3919–3927.
   PubMed Web of Science ®Google Scholar
• Strell C, Lang K, Niggemann B, et al. Surface molecules regulating rolling and adhesion to endothelium of neutrophil granulocytes and MDA-MB-468 breast carcinoma cells and their interaction. Cell Mol Life Sci. 2007;64(24):3306–3316.
   PubMed Web of Science ®Google Scholar
• Kang T, Zhu Q, Wei D, et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano. 2017;11(2):1397–1411.
   PubMed Web of Science ®Google Scholar
• Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(10):593–601.
   PubMed Web of Science ®Google Scholar
• Headland SE, Jones HR, Norling LV, et al. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis. Sci Transl Med. 2015;7(315):315ra190.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Dehaini D, Zhang Y, et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nature Nanotech. 2018;13(12):1182–1190.
   PubMed Web of Science ®Google Scholar
• Seif M, Einsele H, Loffler J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front Immunol. 2019;10:2711.
   PubMed Web of Science ®Google Scholar
• Ikeda H. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. Int Immunol. 2016;28(7):349–353.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang S, Wang Z. High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials. 2017;135:62–73.
   PubMed Web of Science ®Google Scholar
• Gao J, Chu D, Wang Z. Cell membrane-formed nanovesicles for disease-targeted delivery. J Control Release. 2016;224:208–216.
   PubMed Web of Science ®Google Scholar